Brainomix, an Oxford-born company pioneering AI-powered imaging tools in stroke and lung fibrosis, has clinched an $18 ...

An Oxford University spinout has secured £14 million in funding to advance its "transformative" AI imaging technology in healthcare.

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on InflaRx (IFRX – Research Report). The company’s shares ...

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

Proscia sells digital pathology software and artificial intelligence tools to pharmaceutical companies and diagnostic ...

Brainomix has developed Brainomix 360 Stroke, an AI-powered platform that analyses medical images to support stroke diagnosis and treatment.

Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a ...

Lifesci Capital analyst C. Zhu anticipates that the company will post earnings per share of ($1.83) for the year. Lifesci Capital has a “Outperform” rating and a $20.00 price target on the stock.

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at ...